[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 511
Citations 0
Health Agencies Update
January 23/30, 2013

Varenicline Safety Notice

JAMA. 2013;309(4):333. doi:10.1001/jama.2013.16

A new US Food and Drug Administration (FDA) safety notice suggests a slightly higher occurrence of adverse cardiovascular events is associated with the smoking cessation drug varenicline compared with placebo (http://tinyurl.com/ajrev5j).

After a 2011 clinical trial found an increased risk of serious cardiovascular events among patients with cardiovascular disease using varenicline, the drug's label was revised and the FDA warned the public of the risk (http://tinyurl.com/72zwenq). The agency also required the drug's manufacturer to conduct a meta-analysis of clinical trials of varenicline to compare the risk of major adverse cardiac events (cardiovascular-related death, nonfatal myocardial infarction, and nonfatal stroke) among patients taking the drug and those taking placebo.

First Page Preview View Large
First page PDF preview
First page PDF preview